News

circle_logo2

CalciMedica Appoints Daniel Geffken as Interim Chief Financial Officer

Mr. Geffken brings more than three decades of financial experience to CalciMedica; involved in 12 IPO filings since 2013 LA JOLLA, Calif., November 5, 2020 …

CalciMedica Announces Peer-Reviewed Publication of Positive COVID-19 Data and Initiation of Blinded, Placebo-Controlled Trial of Auxora™ in Patients with Severe COVID-19 Pneumonia

Study published in Critical Care journal shows patients with severe COVID-19 pneumonia treated with Auxora and standard of care had substantially improved outcomes compared to …

CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies

Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate …

CalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia

Median time to recovery was more than two times faster for patients treated with Auxora plus standard of care compared to standard of care alone …

CalciMedica Appoints Robert N. Wilson as Co-Chairman of the Board of Directors and Eric W. Roberts as Vice Chairman

Robert N. Wilson was Former Johnson & Johnson Vice Chairman Board Member, Eric W. Roberts, named Vice Chairman and Chairman of the Strategic Transactions and …

Scroll to Top